You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Computerized Robotic Delayering and Polishing System
SBC: SPECTRAL ENERGIES LLC Topic: DMEA18B001The proposed research and technical objectives in this project deal with computerized automatic delayering and polishing system that would be applicable to both commercial and government semiconductor device research and development with applications including Failure Analysis (FA), Fault Isolation (FI), and Reverse Engineering (RE) of semiconductor microelectronic devices. This project could hel ...
STTR Phase I 2019 Department of DefenseDefense Microelectronics Activity -
Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Virus-Like Particle Based pan-Marburgvirus Vaccine
SBC: LUNA INNOVATIONS INCORPORATED Topic: CBD18A002Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense